InsiderSignal.AI

InsiderSignal.ai

KLRS - Kalaris Therapeutics, Inc.

Insider Purchase by Akkaraju Srinivas (Dir, 10%)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

2 months ago, Akkaraju Srinivas, serving as Dir, 10% owner at Kalaris Therapeutics, Inc. (KLRS), purchased 479,847 shares at $10.42 per share, for a total transaction value of $5,000,006.00. Following this transaction, Akkaraju Srinivas now holds 12,948,081 shares of KLRS.

This purchase represents a 4.00% increase in Akkaraju Srinivas's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, December 18, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, February 17, 2026, 61 days after the trade was made.

Kalaris Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Akkaraju Srinivas

Akkaraju Srinivas

Dir, 10%

Srinivas Akkaraju, M.D., Ph.D. is an independent director at Alumis Inc. (ALMS) since March 2024, bringing extensive expertise in life sciences investing and biopharma governance.[[1]](https://fintool.com/app/research/companies/ALMS/people/srinivas-akkaraju)[[3]](https://www.alumis.com/about/) He is the founder and managing member of Samsara BioCapital since March 2017, with nearly 20 years of experience in venture capital and private equity, including roles as General Partner at Sofinnova Ventures (2013–2016), Managing Director at New Leaf Venture Partners (2009–2013), and co-founder of Panorama Capital (2006–2008).[[1]](https://fintool.com/app/research/companies/ALMS/people/srinivas-akkaraju)[[2]](https://dewpointx.com/employee-portraits/srinivas-akkaraju/)[[3]](https://www.alumis.com/about/) Earlier, he worked in Business and Corporate Development at Genentech (1998–2001).[[2]](https://dewpointx.com/employee-portraits/srinivas-akkaraju/)[[4]](https://www.a2bio.com/member/srinivas-akkaraju-m-d-ph-d/) Akkaraju holds an M.D. and Ph.D. in Immunology from Stanford University, and undergraduate degrees in Biochemistry and Computer Science from Rice University.[[1]](https://fintool.com/app/research/companies/ALMS/people/srinivas-akkaraju)[[2]](https://dewpointx.com/employee-portraits/srinivas-akkaraju/)[[3]](https://www.alumis.com/about/) He currently serves on the boards of vTv Therapeutics Inc., Scholar Rock Holding Corporation, Mineralys Therapeutics, Inc., Inventiva S.A., and Syros Pharmaceuticals, Inc., with past directorships at companies like Seagen, Inc. and Intercept Pharmaceuticals.[[1]](https://fintool.com/app/research/companies/ALMS/people/srinivas-akkaraju)[[3]](https://www.alumis.com/about/)[[7]](https://scholarrock.com/our-company/9021/board-of-directors/srini-akkaraju/) Through Samsara BioCapital, he beneficially owns approximately 5% of ALMS voting common stock as of June 2025, and was involved in a November 2025 insider purchase of 276,179 shares at $5.25 via Samsara Opportunity Fund.[[1]](https://fintool.com/app/research/companies/ALMS/people/srinivas-akkaraju)

View full insider profile →

Trade Price

$10.42

Quantity

479,847

Total Value

$5,000,006.00

Shares Owned

12,948,081

Trade Date

Thursday, December 18, 2025

66 days ago

SEC Filing Date

Tuesday, February 17, 2026

Filed 61 days after trade

HEALTHCAREBIOTECHNOLOGY

About Kalaris Therapeutics, Inc.

Company Overview

No company information available
View news mentioning KLRS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4074054

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime